RNA Sequencing Reveals Novel Transcripts from Sympathetic Stellate Ganglia During Cardiac Sympathetic Hyperactivity

Area of Science:

• Cardiovascular Physiology
• Neuroscience
• Molecular Biology

Background:

• Cardiovascular disease is a leading cause of global mortality, with hypertension as a major risk factor.
• Enhanced sympathetic activity contributes to hypertension pathophysiology, but underlying molecular changes are poorly understood.
• There is a clinical need for interventions targeting the root causes of sympathetic hyperactivity in hypertension.

Purpose of the Study:

• To identify critical changes in gene expression (transcriptome) associated with hypertension.
• To investigate the roles of glutamatergic signaling and phosphodiesterase activity in sympathetic ganglia.
• To explore potential therapeutic targets for hypertension and related dysautonomias.

Main Methods:

• Comparative transcriptome analysis between normotensive and spontaneously hypertensive rats.
• Validation of top-scoring genes using quantitative reverse transcription PCR (qRT-PCR).
• Network and enrichment analyses to determine functional pathways, including glutamatergic signaling and phosphodiesterase activity.
• Confirmation of gene transcript presence in human stellate ganglion samples.

Main Results:

• Identified key transcriptome changes in hypertensive rats, with 15 top-scoring genes validated.
• Glutamatergic signaling identified as crucial for modulating calcium (Ca2+) balance in sympathetic ganglia.
• Altered phosphodiesterase activity observed in hypertensive rats, suggesting impaired cyclic nucleotide signaling and disturbed Ca2+ homeostasis.
• Key neurotransmission-related transcripts confirmed in human stellate ganglia, indicating conserved mechanisms.

Conclusions:

• Sympathetic hyperactivity in hypertension is linked to specific molecular alterations in ganglia, including glutamatergic and cyclic nucleotide signaling pathways.
• Impaired Ca2+ homeostasis and altered phosphodiesterase activity are implicated in the pathophysiology of hypertension.
• Identified genes represent potential novel targets for therapeutic interventions against sympathetic hyperactivity in cardiovascular disease and dysautonomias.